Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 28 - Cannabis and Addiction

  • from Part VIII - Special Topics
  • Edited by Deepak Cyril D'Souza, Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine, David Castle, University of Tasmania, Australia, Sir Robin Murray, Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
  • Book:
    Marijuana and Madness
    Published online:
    12 May 2023
    Print publication:
    01 June 2023, pp 299-309

  • Summary

    Although the majority of people who use cannabis do not become addicted, globally there are more people in treatment for cannabis addiction than for any other drug. And as the THC concentration in cannabis has increased, more adolescents are seeking help for cannabis addiction. This chapter addresses the following questions to provide an overview of cannabis addiction. What is the neurobiology that underlies cannabis addiction? What factors make some individuals more vulnerable than others to developing cannabis addiction? Why do only a minority of people who are addicted seek treatment? How effective are currently available pharmacological and psychological treatments? Would delivering therapy remotely increase treatment uptake by reducing stigma? Increasingly across the globe cannabis is available for medicinal use so how can we minimize these patients’ risk of addiction? How can drug policy be used to promote harm reduction by providing a safer, regulated market and lower potency cannabis products?